Article Text

Download PDFPDF

Short report
Biosimilar infliximab use in paediatric IBD
  1. Lisa Richmond1,
  2. Lee Curtis1,
  3. Victoria Garrick1,
  4. Pam Rogers2,
  5. Michelle Wilson3,
  6. Rachel Tayler1,
  7. Paul Henderson2,3,
  8. Richard Hansen1,
  9. David C Wilson3,
  10. Richard K Russell1
  1. 1 Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK
  2. 2 Department of Paediatric Gastroenterology, Royal Hospital for Sick Children, Edinburgh, UK
  3. 3 Child Life and Health, University of Edinburgh, Edinburgh, UK
  1. Correspondence to Lisa Richmond, Paediatric Clinical Research Facility, Neurosciences building, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK; lisa.richmond{at}nhs.net

Abstract

Background Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease.

Methods Prospective clinical data were collected from laboratory reports, electronic patient records and case notes of 40 patients starting Remsima for the first time. Disease activity scores together with blood and stool biomarkers were used to assess response.

Results Our data set highlights that Remsima was associated with a significant clinical and biochemical improvement (p<0.01 or less for all parameters assessed) in Crohn’s disease post induction. There were no significant safety issues noted. The total cost saving was £47 800, representing a 38% reduction from originator.

Conclusion We found that biosimilar infliximab is as effective as originator infliximab and its use is associated with significant cost savings.

  • infliximab
  • biosimilars
  • paediatric
  • inflammatory bowel disease

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests LR: conference fees and travel from Tillotts. VG: conference fees and travel from AbbVie. RT: speaker’s fees and conference attendance from Nutricia. PH: lecture fees from Dr Falk. RH: speaker’s fees, conference support or consultancy fees from Nutricia, Dr Falk, MSD Immunology and 4D Pharma. DCW: lecture fees, consultancy, travel support from AbbVie; consultancy from Takeda; and financial support for research by MSD. RKR: speaker’s fees, travel support and participated in medical board meetings with AbbVie, Napp and Nestle. All other listed authors have no declared conflicts of interest.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.